EXACT Sciences Corporation (EXAS) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
EXACT Sciences Corporation stock (EXAS) is currently trading at $104.91. EXACT Sciences Corporation PS ratio (Price-to-Sales) is 6.17. Analyst consensus price target for EXAS is $106.30. WallStSmart rates EXAS as Sell.
- EXAS PE ratio analysis and historical PE chart
- EXAS PS ratio (Price-to-Sales) history and trend
- EXAS intrinsic value — DCF, Graham Number, EPV models
- EXAS stock price prediction 2025 2026 2027 2028 2029 2030
- EXAS fair value vs current price
- EXAS insider transactions and insider buying
- Is EXAS undervalued or overvalued?
- EXACT Sciences Corporation financial analysis — revenue, earnings, cash flow
- EXAS Piotroski F-Score and Altman Z-Score
- EXAS analyst price target and Smart Rating
EXACT Sciences Corporation
📊 No data available
Try selecting a different time range
Smart Analysis
EXACT Sciences Corporation (EXAS) · 9 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in market cap, revenue growth, institutional own.. Concerns around peg ratio and return on equity. Significant fundamental concerns warrant caution or avoidance.
EXACT Sciences Corporation (EXAS) Key Strengths (3)
86.48% of shares held by major funds and institutions
Large-cap company with substantial market presence
Strong revenue growth at 23.10% annually
EXACT Sciences Corporation (EXAS) Areas to Watch (6)
PEG ratio is negative or unavailable
Company is destroying shareholder value
Losing money on operations
Company is losing money with a negative profit margin
Very expensive at 8.3x book value
Premium valuation at 6.2x annual revenue
Supporting Valuation Data
EXACT Sciences Corporation (EXAS) Detailed Analysis Report
Overall Assessment
This company scores 30/100 in our Smart Analysis, earning a F grade. Out of 9 metrics analyzed, 3 register as strengths (avg 9.0/10) while 6 fall into concern territory (avg 1.0/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Institutional Own., Market Cap, Revenue Growth. Growth metrics are encouraging with Revenue Growth at 23.10%.
The Bear Case
The primary concerns are PEG Ratio, Return on Equity, Operating Margin. Some valuation metrics including PEG Ratio (N/A), Price/Sales (6.17), Price/Book (8.34) suggest expensive pricing. Profitability pressure is visible in Return on Equity at -8.66%, Operating Margin at -9.28%, Profit Margin at -6.40%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether PEG Ratio improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -8.66% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 23.10% strong but requiring continuation.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. PEG Ratio and Return on Equity are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
EXAS Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
EXAS's Price-to-Sales ratio of 6.17x trades at a deep discount to its historical average of 96.19x (2th percentile). The current valuation is 99% below its historical high of 889.28x set in Dec 2014, and 2% above its historical low of 6.07x in Mar 2026.
Compare EXAS with Competitors
Top DIAGNOSTICS & RESEARCH stocks by market cap
Compare any two stocks →WallStSmart Analysis Synopsis
Data-driven financial summary for EXACT Sciences Corporation (EXAS) · HEALTHCARE › DIAGNOSTICS & RESEARCH
The Big Picture
EXACT Sciences Corporation is a strong growth company balancing expansion with improving profitability. Revenue reached 3.2B with 23% growth year-over-year. The company is currently unprofitable, posting a -6.4% profit margin.
Key Findings
Generating 120M in free cash flow and 152M in operating cash flow. Earnings are translating into actual cash generation.
The company is unprofitable with a -6.4% profit margin. The path to breakeven will be the key catalyst.
What to Watch Next
Growth sustainability: can EXACT Sciences Corporation maintain 23%+ revenue growth, or will competition slow it down?
Sector dynamics: monitor DIAGNOSTICS & RESEARCH industry trends, competitive moves, and regulatory changes that could impact EXACT Sciences Corporation.
Bottom Line
EXACT Sciences Corporation offers an attractive blend of growth (23% revenue expansion) and improving fundamentals. The company is transitioning from pure growth to profitable growth, a critical inflection point. Watch for sustained margin expansion as the key signal.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions(20 last 3 months)
Data sourced from SEC Form 4 filings
Last updated: 10:06:56 AM
About EXACT Sciences Corporation(EXAS)
NASDAQ
HEALTHCARE
DIAGNOSTICS & RESEARCH
USA
Exact Sciences Corporation offers cancer screening and diagnostic test products in the United States and internationally. The company is headquartered in Madison, Wisconsin.